Disease Information

General Information of the Disease (ID: DIS00381)

• Name: Parotid gland cancer
• ICD: ICD-11: 2B67

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Clinical Trial Drug(s) 1 drug(s) in total

Capivasertib

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: RAC-alpha serine/threonine-protein kinase (AKT1) [1]

• Sensitive Disease: Parotid gland cancer [ICD-11: 2B67.0]
• Molecule Alteration: Missense mutation; p.E17K (c.49G>A)
• Sensitive Drug: Capivasertib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Breast; .
• Mechanism Description: The missense mutation p.E17K (c.49G>A) in gene AKT1 cause the sensitivity of Capivasertib by aberration of the drug's therapeutic target

References

• Ref 1: Capivasertib Active against AKT1-Mutated CancersCancer Discov. 2019 Jan;9(1):OF7. doi: 10.1158/2159-8290.CD-NB2018-153. Epub 2018 Nov 14.